LEADER 04886nam 2201585z- 450 001 9910557129403321 005 20231214133304.0 035 $a(CKB)5400000000040760 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68362 035 $a(EXLCZ)995400000000040760 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNovel Biomarkers in Alzheimer's Disease 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (442 p.) 311 $a3-03943-903-0 311 $a3-03943-904-9 330 $aAlzheimer?s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD. 606 $aMedicine$2bicssc 610 $aflotillin 610 $aAlzheimer's disease 610 $abiomarker 610 $aexosomes 610 $abeta-amyloid 610 $aTau 610 $aaging 610 $abiomarkers 610 $acytokines 610 $acognitive decline 610 $ametabolomics 610 $aneuroinflammation 610 $amultivariate analysis 610 $aphysical performance 610 $aperson-tailored 610 $aPET/CT 610 $a(18F)FDG 610 $aneuropsychological assessment 610 $aAPP mutations 610 $aAPOE alleles 610 $aPSEN1 610 $aPSEN2 610 $agermline mutations 610 $alate onset AD 610 $aearly onset AD 610 $afamilial AD 610 $agenetics of AD 610 $amitochondrial spare respiratory capacity 610 $amitochondrial 610 $amembrane potential 610 $aglycolytic reserve 610 $asemantic memory 610 $aphonemic fluency 610 $aepisodic memory 610 $aneuropsychology 610 $aneuroimaging 610 $aAlzheimer's disease 610 $amild cognitive impairment 610 $aEEG 610 $aTMS 610 $aobesity 610 $adiabetes 610 $ainflammation 610 $aAmyloid Beta 610 $amitochondrial dysfunction 610 $anutrition 610 $aomega-3 fatty acids 610 $aantioxidant 610 $acarotenoids 610 $avitamin E 610 $acognition 610 $aolder adults 610 $aageing 610 $asubjective cognitive decline 610 $aclock genes 610 $aClock 610 $aApoE 610 $acardiovascular risk factors 610 $aAlzheimer disease 610 $asemantic priming 610 $aamyloid beta 610 $acerebrospinal fluid 610 $aamyloid beta peptide 610 $atotal tau 610 $aphosphorylated tau 610 $adiagnosis 610 $adrug development 610 $aclinical trials 610 $adiagnostic research 610 $avirus 610 $abacteria 610 $adementia 610 $ablood 610 $abehavioral and psychological symptoms of dementia (BPSD) 610 $aAlzheimer's disease (AD) 610 $aneuropsychiatry inventory scale (NPI) 610 $aendophenotypes 610 $aCART analysis 610 $aMTHFR 610 $aAPOE 610 $aCOMT 610 $agenetic variants 610 $aearly diagnosis 610 $abiofluids 610 $aamyloid cascade hypothesis 610 $aglucose metabolism 610 $aadipose tissue dysfunction 610 $aenergetic metabolism 610 $alysosomes dysfunction 610 $aType-3-Diabetes 610 $aneurodegeneration 610 $aamyloid 610 $atau 610 $asoluble TREM2 610 $aNfL 610 $aMultiplex 610 $aSiMoA 610 $adiagnostics 610 $amessenger RNA 610 $amicroRNA 610 $aneurotropic microbes 610 $aprecision medicine 610 $aprognostics 610 $asynaptic biomarkers 610 $aneurofilament light chain 615 7$aMedicine 700 $aVilla$b Chiara$4edt$01280948 702 $aVilla$b Chiara$4oth 906 $aBOOK 912 $a9910557129403321 996 $aNovel Biomarkers in Alzheimer's Disease$93031265 997 $aUNINA